Clinical Trials Logo

Pituitary Adenoma clinical trials

View clinical trials related to Pituitary Adenoma.

Filter by:

NCT ID: NCT06326853 Not yet recruiting - Acromegaly Clinical Trials

Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacological Novel Targets Based on Experimental and Clinical Models

Start date: March 2024
Phase:
Study type: Observational

The goal of this observational study is to evaluate, retrospectively and prospectively, the effect of different hormonal and neuropeptide dysfunctions on the body composition of patients suffering from hypothalamic-pituitary pathologies, and to evaluate the potential beneficial effect of surgical and medical treatments with agonists and antagonists of hypothalamic neuropeptides, currently available, on the development and treatment of adiposity and negative cross-talk between adiposity and muscle/bone tissue

NCT ID: NCT06234553 Active, not recruiting - Pituitary Adenoma Clinical Trials

Application of Radiomics in the Diagnosis and Treatment Prediction of Pituitary Adenoma

RIPA
Start date: January 1, 2022
Phase:
Study type: Observational

The images of patients with Pituitary adenoma were collected and analyzed based on the methods of radiomics.

NCT ID: NCT06156020 Recruiting - Pituitary Adenoma Clinical Trials

Outcome Analysis of Endoscopic Resection of Pituitary Adenomas

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

The goal of this prospective study is to learn about the operative outcomes in patients with pituitary adenoma who receive endoscopic resection. The main question it aims to answer is: • What are the outcomes of patient following endoscopic resection? including visual, hormonal, survival, and functional outcomes. Participants' data including clinical history, laboratory data, radiographic images, intraoperative videos will be evaluated and analyzed.

NCT ID: NCT06053437 Completed - Pituitary Adenoma Clinical Trials

Prognostic Indicators in Pituitary Adenoma Surgery: a Comprehensive Analysis of Surgical Outcomes and Complications.

Hyp'Op
Start date: February 1, 2023
Phase:
Study type: Observational

Predicting the outcome of pituitary surgery, particularly the risk of complications, is a critical determinant in selecting the appropriate treatment modality for patients. To date, only a limited number of risk factors have been identified for complications following pituitary surgery, including tumor size, younger age, and previous surgical intervention. Furthermore, existing studies have demonstrated that prolactin levels can serve as a surrogate marker for assessing pituitary function, specifically revealing associations between elevated prolactin levels and anterior pituitary insufficiencies. In a retrospective study on the "HYP'OP" cohort, the aim of the study is to identify predictive factors for both surgical outcomes and complications.

NCT ID: NCT06015802 Recruiting - Clinical trials for Neuroendocrine Tumors

Predictive Value of Serum and Tissue Molecular Markers and Imaging Features in the Invasiveness and Prognosis of Pituitary Neuroendocrine Tumors

Start date: April 1, 2021
Phase:
Study type: Observational

As the clinical manifestations of pituitary neuroendocrine tumors vary greatly, 2.7-15% of them are resistant to conventional treatments such as surgery, drug therapy and radiotherapy, and often relapse or regrow in the early postoperative period, which is invasive and has a poor prognosis. Therefore, it is important to find imaging, histological or serum molecular markers for early prediction of the invasiveness and clinical prognosis of pituitary neuroendocrine tumors. The aim of this study is to observe the changes of biomarkers and imaging features in serum or tissues of pituitary neuroendocrine tumors during the course of disease and treatment, and to explore the biomarkers and imaging features that can predict the proliferation, progression and recurrence risk of pituitary neuroendocrine tumors after medical or surgical treatment.

NCT ID: NCT05822817 Recruiting - Pituitary Adenoma Clinical Trials

Comparison of Postoperative Recovery of Sevoflurane and Propofol After Transsphenoidal Surgery

Start date: May 3, 2023
Phase: Phase 4
Study type: Interventional

Currently, total intravenous anesthesia (TIVA) and inhaled anesthesia are both commonly used for transsphenoidal pituitary adenoma resection. However, optimal choice for anesthesia maintenance in transsphenoidal surgery remains unclear. Previous studies focusing on this question provided fragmentary assessment and controversial results. The goal of this clinical trial is to investigate whether propofol and sevoflurane have different effect on post-anesthetic recovery after transsphenoidal resection of pituitary adenoma.

NCT ID: NCT05727605 Recruiting - Glioma Clinical Trials

Neurocognition After Radiotherapy in CNS- and Skull-base Tumors

NARCiS
Start date: February 8, 2023
Phase: N/A
Study type: Interventional

The goal of this multicenter prospective longitudinal study is to study the long-term impact of multimodal treatment (chemotherapy, radiotherapy and surgery) in adult brain and base of skull tumors on neurocognitive functioning. All included patients will complete a self-report inventory (subjective cognitive functioning, QoL, confounders), a cognitive test battery, an advanced MR at multiple timepoints. Moreover, toxicity will be scored according to the CTCAEv5.0 in these patients over time.

NCT ID: NCT05466357 Recruiting - Pituitary Adenoma Clinical Trials

Application Research on Endoscopic Pseudocapsule-Based Resection for Pituitary Adenomas

Start date: December 28, 2022
Phase: N/A
Study type: Interventional

Pituitary adenomas are one of the most common primary central nervous system tumors and have an estimated prevalence of 17%. Management of pituitary adenomas involves a multidisciplinary approach that can incorporate surgical, medical, and/or radiation therapies. Over the last two decades, the endoscopic endonasal approach (EEA) has been extensively developed and refined for the resection of pituitary adenomas (PAs). In recent years, extracapsular resection (ER), which emphasized the importance of the pseudocapsule between the adenoma and surrounding normal gland tissue as a surgical plane, was adopted for more radical resection of the tumor. Therefore, dedicated high-resolution magnetic resonance imaging (MRI) protocols have been proposed to detect pituitary adenoma and accurately guide surgical removal. The evaluation of preoperative imaging for pseudocapsule is very important to the surgical method. Depending on different tumor sizes and pseudocapsule development, investigators adopted different resection strategies. To accomplish complete PA removal and minimize the impact on pituitary functions, intraoperative navigation was used to identify the tumor pseudocapsule, also the suspicious tissue was sent to the pathology department for histopathology intraoperatively. Long-term postoperative follow-up imaging and endocrine data were used to evaluate tumor prognosis. Standardized management and established biobank is critical for pituitary adenomas.

NCT ID: NCT05448690 Recruiting - Surgery Clinical Trials

Comparative Effectiveness of Different Surgical Approaches for Giant Pituitary Adenomas

Start date: January 1, 2022
Phase:
Study type: Observational

The surgical treatment strategy for giant invasive pituitary adenoma is one of the current hot spots in the field of clinical research on pituitary adenoma. A comprehensive literature search resulted in numerous previous studies to investigate the efficacy, advantages and disadvantages of different surgical options. A single approach (transnasal or craniotomy) is theoretically less invasive and has a shorter hospital stay for the patient, but may result in postoperative bleeding due to residual tumor and damage to the intracranial vessels adhering to the tumor. The advantage of the combined approach is that the tumor can be removed to the greatest extent possible. In addition, postoperative suprasellar hemorrhage can be prevented by careful hemostasis or intracranial drainage by the transcranial team if necessary. In this way, the risk of postoperative bleeding due to residual tumor can be significantly reduced. In some cases, waiting a few months after the initial surgery for a second-stage procedure may also be an option when the patient's condition does not allow for a combined access procedure, when the tumor is hard, or when the blood preparation is insufficient. However, staged surgery increases the financial burden on the patient, and local scar formation may make second-stage surgery more difficult and decrease the likelihood of endocrine remission of functional pituitary tumors. Given the complexity of the treatment of giant invasive pituitary adenoma, there is a need to conduct studies comparing the combined transnasal cranial approach, the single access transnasal or cranial approach, and the staged approach simultaneously to assess whether the combined transnasal cranial approach is superior to the single access transnasal or cranial approach or the staged approach in improving the tumor resection rate in giant invasive pituitary adenoma.

NCT ID: NCT05338125 Terminated - Pituitary Adenoma Clinical Trials

Electrophysiology of the Human Pituitary Gland

Start date: December 10, 2020
Phase: N/A
Study type: Interventional

Measurment of electrophysiological properties of the human pituitary gland during removal of a pituitary adenoma. Assessment if these properties are sufficient for intra-operative identification of different tissues.